Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Among authors: prieto gonzalez jm. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test).
Meca-Lallana JE, Prieto-González JM, Jimenez-Veiga J, Carreón-Guarnizo E, Jiménez-Martín I, Hernández-Clares R, Sistiaga-Berrondo A, Carles-Dies R, García-Molina E, Cerdán-Sánchez M, Costa-Arpín E, Croitoru I, Castillo-Triviño T, Iniesta-Martinez F, García-Pérez E, Olascoaga-Urtaza J. Meca-Lallana JE, et al. Among authors: prieto gonzalez jm. Mult Scler Relat Disord. 2019 Feb;28:50-56. doi: 10.1016/j.msard.2018.12.003. Epub 2018 Dec 3. Mult Scler Relat Disord. 2019. PMID: 30553169
Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology.
Fernandez O, Costa-Frossard L, Martínez-Ginés ML, Montero P, Prieto-González JM, Ramió-Torrentà L. Fernandez O, et al. Among authors: prieto gonzalez jm. Front Neurol. 2021 Sep 27;12:722801. doi: 10.3389/fneur.2021.722801. eCollection 2021. Front Neurol. 2021. PMID: 34646229 Free PMC article.
Consensus on early detection of disease progression in patients with multiple sclerosis.
Meca-Lallana JE, Casanova B, Rodríguez-Antigüedad A, Eichau S, Izquierdo G, Durán C, Río J, Hernández MÁ, Calles C, Prieto-González JM, Ara JR, Uría DF, Costa-Frossard L, García-Merino A, Oreja-Guevara C. Meca-Lallana JE, et al. Among authors: prieto gonzalez jm. Front Neurol. 2022 Jul 28;13:931014. doi: 10.3389/fneur.2022.931014. eCollection 2022. Front Neurol. 2022. PMID: 35968319 Free PMC article.
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: prieto gonzalez jm. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis.
Fernández Fernández Ó, Costa-Frossard L, Martínez Ginés ML, Montero Escribano P, Prieto González JM, Ramió-Torrentà L, Aladro Y, Alonso Torres A, Álvarez Rodríguez E, Labiano-Fontcuberta A, Landete Pascual L, Miralles Martínez A, Moral Torres E, Oliva-Nacarino P. Fernández Fernández Ó, et al. Among authors: prieto gonzalez jm. Front Neurol. 2024 Apr 19;15:1371644. doi: 10.3389/fneur.2024.1371644. eCollection 2024. Front Neurol. 2024. PMID: 38708001 Free PMC article.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Platas M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X. Meca-Lallana JE, et al. Among authors: gonzalez platas m, prieto gonzalez jm. Neurologia (Engl Ed). 2020 Jan 25;37(8):615-630. doi: 10.1016/j.nrl.2019.11.003. Print 2022 Oct. Neurologia (Engl Ed). 2020. PMID: 31987648 Free article. English, Spanish.
Expert-Agreed Practical Recommendations on the Use of Cladribine.
Meca-Lallana V, García Domínguez JM, López Ruiz R, Martín-Martínez J, Arés Luque A, Hernández Pérez MA, Prieto González JM, Landete Pascual L, Sastre-Garriga J. Meca-Lallana V, et al. Among authors: prieto gonzalez jm. Neurol Ther. 2022 Dec;11(4):1475-1488. doi: 10.1007/s40120-022-00394-0. Epub 2022 Sep 6. Neurol Ther. 2022. PMID: 36068429 Free PMC article.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Plata M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X. Meca-Lallana JE, et al. Among authors: gonzalez plata m, prieto gonzalez jm. Neurologia (Engl Ed). 2022 Oct;37(8):615-630. doi: 10.1016/j.nrleng.2019.11.001. Epub 2020 Mar 12. Neurologia (Engl Ed). 2022. PMID: 36195374 Free article.
28 results